Design and protocol for a pragmatic randomised study to optimise screening, prevention and care for tuberculosis and HIV in Malawi (PROSPECT Study)

MacPherson, Peter ORCID: 0000-0002-0329-9613, Webb, Emily, Lalloo, David ORCID: 0000-0001-7680-2200, Nliwasa, Marriott, Maheswaran, Hendramoorthy ORCID: 0000-0002-7375-4845, Joekes, Elizabeth, Phiri, Dama ORCID: 0000-0002-1868-9008, Squire, Bertie ORCID: 0000-0001-7173-9038, Pai, Madhukar and Corbett, Elizabeth (2018) Design and protocol for a pragmatic randomised study to optimise screening, prevention and care for tuberculosis and HIV in Malawi (PROSPECT Study). Wellcome Open Research, 3. p. 61.

Text Macpherson et al.pdf - Published version Download (1MB) | Preview

Abstract

Background: Adults seeking diagnosis and treatment for tuberculosis (TB) and HIV in low-resource settings face considerable barriers and have high pre-treatment mortality. Efforts to improve access to prompt TB treatment have been hampered by limitations in TB diagnostics, with considerable uncertainty about how available and new tests can best be implemented. Design and methods: The PROSPECT Study is an open, three-arm pragmatic randomised study that will investigate the effectiveness and cost-effectiveness of optimised HIV and TB diagnosis and linkage to care interventions in reducing time to TB diagnosis and prevalence of undiagnosed TB and HIV in primary care in Blantyre, Malawi. Participants (≥ 18 years) attending a primary care clinic with TB symptoms (cough of any duration) will be randomly allocated to one of three groups: (i) standard of care; (ii) optimised HIV diagnosis and linkage; or (iii) optimised HIV and TB diagnosis and linkage. We will test two hypotheses: firstly, whether prompt linkage to HIV care should be prioritised for adults with TB symptoms; and secondly, whether an optimised TB triage testing algorithm comprised of digital chest x-ray evaluated by computer-aided diagnosis software and sputum GeneXpert MTB/Rif can outperform clinician-directed TB screening. The primary trial outcome will be time to TB treatment initiation by day 56, and secondary outcomes will include prevalence of undiagnosed TB and HIV, mortality, quality of life, and cost-effectiveness. Conclusions: The PROSPECT Study will provide urgently-needed evidence under “real-life” conditions to inform clinicians and policy makers on how best to improve TB/HIV diagnosis and treatment in Africa. Clinical trial registration: NCT03519425 (08/05/2018)

Item Type:	Article
Uncontrolled Keywords:	Infectious Diseases, Comparative Effectiveness Research, Pediatric AIDS, Tuberculosis, Clinical Research, Rare Diseases, Clinical Trials and Supportive Activities, HIV/AIDS, Health Services, Prevention, Pediatric, 6 Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, 3 Good Health and Well Being
Depositing User:	Symplectic Admin
Date Deposited:	10 Dec 2019 10:30
Last Modified:	12 Apr 2024 00:40
DOI:	10.12688/wellcomeopenres.14598.2
Related URLs:	Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3065586